Killer cell immunoglobulin-like receptors and response to antiviral treatment in Thai patients with chronic hepatitis C virus genotype 3a

Journal of Medical Virology

Volumn 83, Issue 10, 2011, Pages 1733-1737

  Vejbaesya, Sasijit ^a   Nonnoi, Yuwatida ^a   Tanwandee, Tawesak ^a   Srinak, Duangporn ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Hepatitis C; KIR; Thai

Indexed keywords

ANTIVIRUS AGENT; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION WITH SEQUENCE SPECIFIC PRIMER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HLA-A ANTIGENS; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, KIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THAILAND; TREATMENT OUTCOME;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 3;

EID: 80051598681     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22153     Document Type: Article

References (19)

1. Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B. 2008. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 118: 1017-1026.
2. Asselah T, Bieche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. 2007. Genetics, genomics and proteomics: Implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 27: 13-27.
3. Bunce M, O Neill CM, Barnardo MCNM, Krausa P, Browning MJ, Morris PJ, Welsh KI. 1995. Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46: 355-367.
4. Carneiro VL, Lemaire DC, Bendicho MT, Souza SL, Cavaicante LN, Angelo AL, Freire SM, Mendes CM, Santana N, Lyra LG, Lyra AC. 2010. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: A comparison between sustained virological responders and non-responders. Liver Int 30: 564-573.
5. Chinuvati T, Poovorawan Y, Luengrojanakul P. 1991. The prevalence of hepatitis C virus antibody in high risk groups of Thai children and adults. Gastroenterol Jpn 26: 176-180.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
7. Hollenbach JA, Meenagh A, Sleator C, Alaez C, Bengoche M, Canossi A, Contreras G, Creary L, Evseeva I, Gorodezky C, Hardie RA, Karlsen TH, Lie B, Luo M, Martinetti M, Navarette C, de Oliveira DC, Ozzella G, Pasi A, Pavlova E, Pinto S, Porto LC, Santos P, Slavcev A, Srinak D, Tavoularis S, Tonks S, Trachtenberg E, Vejbaesya S, Middleton D. 2010. Report from the killer immunoglobulin-like receptor (KIR) anthropology component of the 15th International histocompatibility workshop: Worldwide variation in the KIR loci and further evidence for the co-evolution of KIR and HLA. Tissue Antigens 76: 9-17.
8. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. 2002. Killer Ig-like receptor haplotype analysis by gene content: Evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 169: 5118-5129.
9. Kau A, Vermehren J, Sarrazin C. 2008. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49: 634-651.
10. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M, Cox C, Little AM, Alexander GJ, Cramp ME, Obrien SJ, Rosenberg WMC, Thomas DL, Carrington M. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872-874.
11. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WMC, Cramp ME, Khakoo SI. 2010. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51: 1168-1175.
12. Middleton D, Curran M, Maxwell L. 2002. Natural killer cells and their receptors. Transplant Immunology 10: 147-164.
13. Norman PJ, Carrington CVF, Byng M, Maxwell LD, Curran MD, Stephens HAF, Chandanayingyong D, Verity DH, Hameed K, Ramdath DD, Vaughan RW. 2002. Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and South Asian populations. Genes Immun 3: 86-95.
14. Romero V, Azocar J, Zúñiga J, Clavijo OP, Terreros D, Gu X, Husain Z, Chung RT, Amos C, Yunis EJ. 2008. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in hepatitis C virus infection outcome. Mol Immunol 45: 2429-2436.
15. Strader DB, Wright T, Thomas DL, Seeff LB. 2004. Diagnosis, management and treatment of hepatitis C. Hepatology 39: 1147-1171.
16. Tong MJ, EL-Farra NS, Reikes AR, Co RL. 1995. Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 332: 1463-1468.
17. Verachai V, Phutiprawan T, Theambooniers A, Chinchai T, Tanprasert S, Haagmans BL, Osterhaus AD, Poovorawan Y. 2002. Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand. Southeast Asian J Trop Med Public Health 33: 849-851.
18. Vidal-Castiñeira JR, López-Vázquez A, Díaz-Peña R, Alonso-Arias R, Martínez-Borra J, Perez Fernández-Suárez J, Melón S, Prieto J, Rodrigo L, López-Larrea C. 2010. Effect of killer Immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 84: 475-481.
19. Zuniga J, Romero V, Azocar J, Terreros D, Vargas-Rojas MI, Torres-Garcia D, Jimenez L, Vargas-Alarcon G, Granados-Montiel JG, Husain Z, Chung RT, Alper CA, Yunis EJ. 2009. Protective KIR-HLA interactions for HCV infection in intravenous drug users. Mol Immunol 46: 2723-2727.